Table 2. Therapeutic efficacy and Immune responses using IL-2 receptor γ-chain gene disrupted SCID-PBL/hu models.
| (A) | Therapeutic efficacy | |
|---|---|---|
| Treated | CFU of TB (log) | |
| (-) | 6.03 ± 0.06 | |
| HSP65 DNA + IL-12 DNA vaccine | 5.40 ± 0.97 |
| (B) | Immune reponses | human CTL and T cell proliferation |
|---|---|---|
| IL-2 R γ-chain(−/−) SCID PBL-hu | human CTL (+++) human T cell proliferation (+++) |
|
| CB17-SCID PBL-hu | human CTL (+) human Tcell proliferation (+) |
Therapeutic efficacy of HVJ-envelope / HSP65DNA + IL-12DNA, using in vivo humanized immune models of IL-2 receptor γ-chain disrupted NOD-SCID mice (SCID-PBL/hu). Groups of animals were treated with 3 times with HVJ-envelope / HSP65DNA + IL-12DNA (50ug i.m.) . Ten days after the third vaccination, mice were sacrificed and CFU of TB in the liver of mice were accessed as described in Materials and Methods. One × 107 PBL from a healthy human volunteer were injected i.p. into IL-2 receptorγ-chain disrupted NOD-SCID mice. Twenty one days after injection of PBL, mice were challenged with 5 × 105 H37Rv i.v. and then treated with vaccine. *Student’s t-test was used to compare the CFU of TB of each group (p < 0.05). Human immune responses [human CTL activity and human T cell proliferation against alloantigen (CESS cells)] of IL-2 receptor γ-chain (−/−) NOD SCID PBL-hu mice were compared with those of CB17-NOD-SCID PBL-hu mice. (+), weak; (+++), very strong.